203 related articles for article (PubMed ID: 12454812)
21. Sentinel lymph node biopsy is associated with improved survival compared to level I & II axillary lymph node dissection in node negative breast cancer patients.
Langer I; Guller U; Hsu-Schmitz SF; Ladewig A; Viehl CT; Moch H; Wight E; Harder F; Oertli D; Zuber M
Eur J Surg Oncol; 2009 Aug; 35(8):805-13. PubMed ID: 19046846
[TBL] [Abstract][Full Text] [Related]
22. Management and outcomes of isolated axillary node recurrence in breast cancer.
Konkin DE; Tyldesley S; Kennecke H; Speers CH; Olivotto IA; Davis N
Arch Surg; 2006 Sep; 141(9):867-72; discussion 872-4. PubMed ID: 16983030
[TBL] [Abstract][Full Text] [Related]
23. Nuclear morphometry and mitotic indexes as prognostic factors in breast cancer.
Aaltomaa S; Lipponen P; Eskelinen M; Alhava E; Syrjänen K
Eur J Surg; 1991 May; 157(5):319-24. PubMed ID: 1678644
[TBL] [Abstract][Full Text] [Related]
24. Survival outcomes in node-negative breast cancer patients evaluated with complete axillary node dissection versus sentinel lymph node biopsy.
Cox C; White L; Allred N; Meyers M; Dickson D; Dupont E; Cantor A; Ly Q; Dessureault S; King J; Nicosia S; Vrcel V; Diaz N
Ann Surg Oncol; 2006 May; 13(5):708-11. PubMed ID: 16538416
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
[TBL] [Abstract][Full Text] [Related]
26. The prognostic significance of axillary lymph-node micrometastases in breast cancer patients.
Kuijt GP; Voogd AC; van de Poll-Franse LV; Scheijmans LJ; van Beek MW; Roumen RM
Eur J Surg Oncol; 2005 Jun; 31(5):500-5. PubMed ID: 15922886
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
[TBL] [Abstract][Full Text] [Related]
28. Patients with breast cancer and negative sentinel lymph node biopsy without additional axillary lymph node dissection: a follow-up study of up to 5 years.
Domènech A; Benitez A; Bajén MT; Pla MJ; Gil M; Martín-Comín J
Oncology; 2007; 72(1-2):27-32. PubMed ID: 17998787
[TBL] [Abstract][Full Text] [Related]
29. Prediction of axillary lymph node status of breast cancer patients by tumorbiological factors of the primary tumor.
Fehm T; Maul H; Gebauer S; Scharf A; Baier P; Sohn C; Jäger W; Gebauer G
Strahlenther Onkol; 2005 Sep; 181(9):580-6. PubMed ID: 16170485
[TBL] [Abstract][Full Text] [Related]
30. Nuclear profiles of cancer cells reveal the metastatic potential of gastric cancer.
Ikeguchi M; Cai J; Oka S; Gomyou Y; Tsujitani S; Maeta M; Kaibara N
J Pathol; 2000 Sep; 192(1):19-25. PubMed ID: 10951395
[TBL] [Abstract][Full Text] [Related]
31. Percent positive axillary involvement predicts for the development of brain metastasis in high-risk patients with nonmetastatic breast cancer receiving post-mastectomy radiotherapy.
Atahan IL; Ozyigit G; Yildiz F; Gurkaynak M; Selek U; Sari S; Hayran M
Breast J; 2008; 14(3):245-9. PubMed ID: 18433402
[TBL] [Abstract][Full Text] [Related]
32. Supraclavicular nodal failure in patients with one to three positive axillary lymph nodes treated with breast conserving surgery and breast irradiation, without supraclavicular node radiation.
Reddy SG; Kiel KD
Breast J; 2007; 13(1):12-8. PubMed ID: 17214788
[TBL] [Abstract][Full Text] [Related]
33. The lymph node ratio as prognostic factor in node-positive breast cancer.
Voordeckers M; Vinh-Hung V; Van de Steene J; Lamote J; Storme G
Radiother Oncol; 2004 Mar; 70(3):225-30. PubMed ID: 15064006
[TBL] [Abstract][Full Text] [Related]
34. Axillary lymph node nanometastases are prognostic factors for disease-free survival and metastatic relapse in breast cancer patients.
Querzoli P; Pedriali M; Rinaldi R; Lombardi AR; Biganzoli E; Boracchi P; Ferretti S; Frasson C; Zanella C; Ghisellini S; Ambrogi F; Antolini L; Piantelli M; Iacobelli S; Marubini E; Alberti S; Nenci I
Clin Cancer Res; 2006 Nov; 12(22):6696-701. PubMed ID: 17121888
[TBL] [Abstract][Full Text] [Related]
35. Effect of axillary lymphadenectomy on breast carcinoma survival.
Joslyn SA; Konety BR
Breast Cancer Res Treat; 2005 May; 91(1):11-8. PubMed ID: 15868427
[TBL] [Abstract][Full Text] [Related]
36. An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement.
Barranger E; Coutant C; Flahault A; Delpech Y; Darai E; Uzan S
Breast Cancer Res Treat; 2005 May; 91(2):113-9. PubMed ID: 15868438
[TBL] [Abstract][Full Text] [Related]
37. Association between extent of axillary lymph node dissection and patient, tumor, surgeon, and hospital factors in patients with early breast cancer.
Petrik DW; McCready DR; Sawka CA; Goel V
J Surg Oncol; 2003 Feb; 82(2):84-90. PubMed ID: 12561062
[TBL] [Abstract][Full Text] [Related]
38. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes.
Truong PT; Berthelet E; Lee J; Kader HA; Olivotto IA
Cancer; 2005 May; 103(10):2006-14. PubMed ID: 15812825
[TBL] [Abstract][Full Text] [Related]
39. Omitting axillary lymph node dissection in sentinel node negative breast cancer patients is safe: a long term follow-up analysis.
Torrenga H; Fabry H; van der Sijp JR; van Diest PJ; Pijpers R; Meijer S
J Surg Oncol; 2004 Oct; 88(1):4-7; discussion 7-8. PubMed ID: 15384064
[TBL] [Abstract][Full Text] [Related]
40. Biological significance of occult micrometastases in histologically negative axillary lymph nodes in breast cancer patients using the recent American Joint Committee on Cancer breast cancer staging system.
Kahn HJ; Hanna WM; Chapman JA; Trudeau ME; Lickley HL; Mobbs BG; Murray D; Pritchard KI; Sawka CA; McCready DR; Marks A
Breast J; 2006; 12(4):294-301. PubMed ID: 16848838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
